Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)
Status:
Terminated
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This multi-centre, non-randomized open phase I/randomized phase II study will be conducted in
70 patients (10 in phase I, 60 in phase II) with platinum-refractory recurrent epithelial
cancer of the ovary, fallopian tube or peritoneum. A total of approximately 5 national
centers will participate in phase I of the study. If the starting criteria for phase II of
the study are met at the end of phase I, a total of approximately 20 national centers will
participate in phase II of the study.